The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer
- 3 April 2017
- journal article
- review article
- Published by Springer Science and Business Media LLC in Current Oncology Reports
- Vol. 19 (5), 1-8
- https://doi.org/10.1007/s11912-017-0591-8
Abstract
Recurrent ligand-binding domain ESR1 mutations have recently been detected in a substantial number of patients with metastatic ER+ breast cancer and evolve under the selective pressure of endocrine treatments. In this review, we evaluate the current understanding of the biological and clinical significance of these mutations. The preclinical studies revealed that these mutations lead to constitutive ligand-independent activity, indicating resistance to aromatase inhibitors and decreased sensitivity to tamoxifen and fulvestrant. Retrospective analyses of ESR1 mutations in baseline plasma circulating tumor DNA from completed clinical trials suggest that these mutations are prognostic and predictive of resistance to aromatase inhibitors in metastatic disease. Currently, we are lacking prospective studies to confirm these results and to determine the optimal treatment combinations for patients with the ESR1 mutations. In addition, the clinical development of novel agents to overcome resistance engendered by these mutations is also needed.Keywords
Funding Information
- National Cancer Institute (K08 CA191058-02)
- National Institutes of Health (P50CA058183, P50CA186784, P30CA125123)
- Susan G. Komen for the Cure (PG12221410)
This publication has 41 references indexed in Scilit:
- ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signalingBreast Cancer Research and Treatment, 2016
- Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrantNature Communications, 2016
- Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer PatientsClinical Cancer Research, 2016
- Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast CancerClinical Cancer Research, 2015
- Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancerScience Translational Medicine, 2015
- Detection of Circulating Tumor DNA in Early- and Late-Stage Human MalignanciesScience Translational Medicine, 2014
- The renaissance of endocrine therapy in breast cancerCurrent Opinion in Obstetrics and Gynecology, 2014
- ESR1 ligand-binding domain mutations in hormone-resistant breast cancerNature Genetics, 2013
- Growth factor stimulation induces a distinct ERα cistrome underlying breast cancer endocrine resistanceGenes & Development, 2010
- Genome-wide analysis of estrogen receptor binding sitesNature Genetics, 2006